← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › OTHER HEMATOLOGICAL AGENTS › OTHER HEMATOLOGICAL AGENTS › Drugs used in hereditary angioedema
sebetralstat
B06AC08
Adult Dosing
- 300 mg taken orally as a single dose at the onset of an acute hereditary angioedema (HAE) attack
- A second dose of 300 mg may be taken if symptoms do not improve after 2 to 4 hours
Pediatric Dosing
- Safety and efficacy in pediatric patients below 12 years of age have not been established
- Adolescents aged 12 years and older: 300 mg orally as a single dose at the onset of an HAE attack
Indications
- Treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older
Mechanism of Action
- Inhibitor of plasma kallikrein
- Prevents the proteolytic cleavage of high-molecular-weight kininogen by active plasma kallikrein, thereby blocking the generation of bradykinin and relieving the vascular permeability, vasodilation, and pain associated with acute HAE attacks
Contraindications
- History of hypersensitivity to sebetralstat or any of its excipients
Adverse Reactions
- Abdominal pain
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
Drug Interactions
- Strong or moderate CYP3A4 inhibitors may increase systemic exposure of sebetralstat
- Strong or moderate CYP3A4 inducers may decrease systemic exposure of sebetralstat
- P-glycoprotein (P-gp) inhibitors may affect the absorption and disposition of sebetralstat
Curated Content: Needs Vetting Before Put to Clinical Use